(WASHINGTON, Dec. 4, 2024) – The ASH Research Collaborative (ASH RC), a non-profit organization established by the American Society of Hematology (ASH) to improve the lives of those affected by blood diseases, will present new data at the 66th ASH Annual Meeting and Exposition that feature findings from its multiple myeloma and sickle cell disease research networks.

“The ASH RC has brought the multiple myeloma and sickle cell disease communities together to generate real-world evidence for researchers across the spectrum of both diseases,” said Mark Crowther, MD, MSc, chair of the ASH RC board of directors and chair of the Department of Medicine at McMaster University. “We’re thrilled to showcase our first abstracts at ASH and the research we’re presenting is just the beginning of much more to come.”

The six abstracts and special sessions will discuss how collaborative data sharing and real-world data support clinical outcomes in sickle cell disease and multiple myeloma, including how the SCD Learning Community informed the development of pain plans; COVID-19 outcomes in patients with multiple myeloma; the use of disease-modifying therapies in sickle cell disease; and more.

The presentations include:

Abstract NumberSessionTypeTime
Special SessionASH Research Collaborative Multiple Myeloma Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence GenerationSpecial-Interest Session12/7/24 at 4:00 PM
Special SessionASH Research Collaborative Data Hub Sickle Cell Disease Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence GenerationSpecial-Interest Session12/9/24 at 4:30 PM
1972Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and InfectionsPoster12/7/24 at 5:30 PM
2312Underutilization of Disease-Modifying Therapies in Sickle Cell Disease: A Real-World Analysis from the ASH Research Collaborative Data HubPoster12/7/24 at 5:30 PM
2313High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation StudyPoster12/7/24 at 5:30 PM
2393Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and InfectionsPoster12/7/24 at 5:30 PM
3792eDevelopment of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation NetworkPoster12/8/24 at 6:00 PM

About the ASH Research Collaborative

The ASH Research Collaborative (ASH RC) is a non-profit organization established by the American Society of Hematology (ASH)  to improve the lives of people affected by blood diseases by fostering collaborative partnerships to accelerate research and improve outcomes for individuals with hematologic diseases by advancing treatment developments and generating evidence to support clinical decisions and care.

Contact

Melissa McGue, American Society of Hematology
mmcgue@hematology.org
202-552-4927